DorsaVi : CEO Investor Presentation

nal use only

Investor presentation

July 2022

Executive Summary

		World class		•	Revenue generating medical device company commercialising innovative motion analysis technologies trusted by leading
		technology			international organisations including Medtronic, QBE, Boeing and many more.
		Robust business		•	Product-led business with >90% gross margins - driving operating leverage and scalable revenue profile
		model		•	Growing revenue (~$2.4m in FY22A, up 26% on FY21) with materially lower expenses provide platform for sustainable growth
				• Workplace - aiming to reduce injuries and improve productivity for large scale enterprise customers, while strategically partnering
	Clear and validated
			with insurance companies to accelerate growth
		strategy		•	Clinical - providing physical therapists and leading medical institutions with the tools required to accurately rehabilitate patients
					and partnering with medical technology companies to refine product offering
only			• Revenue growth led by a robust clinical market with momentum building in the workplace sector as corporate customers renew
Multiple growth			their focus on manual handling injuries post COVID
	•	Completed upgrades to Clinical products (Athletic Movement Index), and Workplace products (myVisafe), aim to expand the
pathways
		addressable market, deliver an improved value proposition to customers, and grow recurring revenues
				• Using patented AI and machine learning algorithms to digitise healthcare products

use

Capital raising to

fund growth

initiatives

nal

• Placement and a 1 for 12 fully underwritten non-renounceable entitlement offer to raise a total of approximately $700k o Placement of approximately $400k to new shareholders and existing investors
  o 1 for 12 fully underwritten non-renounceable entitlement offer to eligible shareholders to raise a further $297k
• New shares under the Placement and Entitlement Offer will be issued at a price of $0.010 per share, representing a discount of approximately 12% to the 15-day VWAP of $0.0114 per share1 and 29% to the last close of $0.014 per share1
• The entitlement offer is fully underwritten by various parties from Board and management, and no underwriting fees will be paid
• Funds raised will be used to support the commercialisation of new products in key markets, accelerate the conversion of the sales pipeline, and for ongoing product development and enhancement

1 As at close 26-July-22	2

onlyuseWorld class technology nal

3

Leading provider across two major markets (clinical and workplace)

Unique, validated and proven technology trusted by leading institutions globally

Leading technology

Used and validated by leading institutions1

nal use only

Wearable sensors that measure quality of movement and muscle activity in workplace and clinical settings

Regulatory approvals achieved

• FDA and TGA
• ISO27001 compliant (approved in February 2022)

Trusted solutions

Providing tailored solutions for leading enterprise customers, enabled by best-in-class algorithms and leading data security

1. Selection of past and present customers; Logos are registered trademarks of their respective owners

4

onlyuseRobust business model nal

5